AI Engines For more Details: Perplexityβ Kagi Labsβ Youβ
Non-Small Cell Lung Cancer (NSCLC): Erlotinib is indicated for the treatment of metastatic NSCLC, specifically in patients with tumors that have certain mutations in the epidermal growth factor receptor (EGFR) gene. These mutations make the cancer cells more responsive to EGFR inhibitors like erlotinib. Erlotinib works by inhibiting the activity of EGFR, which is a protein involved in cell growth and division. By blocking EGFR signaling, erlotinib helps slow down or stop the growth and spread of NSCLC tumors.
Pancreatic Cancer: Erlotinib is also approved for the treatment of advanced pancreatic cancer, in combination with another chemotherapy medication called gemcitabine. This combination therapy has been shown to modestly improve overall survival in patients with advanced pancreatic cancer compared to treatment with gemcitabine alone. Erlotinib's mechanism of action in pancreatic cancer is similar to its action in NSCLC, as it inhibits EGFR signaling pathways involved in tumor growth and progression.
Other Cancers: While erlotinib is primarily used in NSCLC and pancreatic cancer, it may also be investigated or used off-label in the treatment of other cancer types, particularly those that overexpress EGFR or have mutations in the EGFR gene.
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive β X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. β Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA β Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. β Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. β Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.217 ]